Cleveland, Ohio 44195

  • Metastatic Cancer


RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Stereotactic radiosurgery may be able to deliver x-rays directly to the tumor and cause less damage to normal tissue. Giving internal radiation therapy after surgery with or without radiosurgery may kill any remaining tumor cells. PURPOSE: This phase II trial is studying how well internal radiation therapy with or without stereotactic radiosurgery works in treating patients who have undergone surgery for newly diagnosed brain metastases.

Study summary:

OBJECTIVES: Primary - Determine the 6-month and 1-year local control rate in patients with newly diagnosed supratentorial brain metastases treated with brachytherapy using the intracavity GliaSite^® Radiation Therapy System (RTS) after surgical resection. Secondary - Determine the overall survival of patients treated with this regimen. - Determine distant brain recurrence in patients treated with this regimen. - Determine the toxic effects of this regimen in these patients. - Assess the quality of life of patients treated with this regimen. OUTLINE: This is a multicenter study. Patients undergo surgical resection of the metastatic brain lesion(s) followed by implantation of the GliaSite^® Radiation Therapy System (RTS). Beginning within the 21 days after surgical resection, patients undergo brachytherapy using the GliaSite^® RTS over 3-7 days. Patients with tumor(s) remaining after surgery also undergo stereotactic radiosurgery 14-42 days after surgical resection and after completion of brachytherapy. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline, at 1 and 3 months, and then every 3 months for 2 years. Patients are followed at 1 and 3 months and then every 3 months for 2 years. PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Histologically confirmed metastatic carcinoma - Stable systemic disease staged within the past 6 weeks - No histology of lymphoma or small cell lung cancer - Newly diagnosed supratentorial metastatic brain lesions - One to three lesions with at least 1 dominant lesion that is amenable to surgical resection as visualized on enhanced MRI PATIENT CHARACTERISTICS: Age - 18 and over Performance status - Karnofsky 70-100% Life expectancy - At least 6 months Hematopoietic - Not specified Hepatic - Not specified Renal - Not specified Cardiovascular - No uncontrolled hypertension - No unstable angina pectoris - No evidence of uncontrolled cardiac dysrhythmia Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No other serious infection or medical illness that would preclude study therapy PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - No prior polifeprosan 20 with carmustine implant (Gliadel^® wafer) for brain metastasis - No prior temozolomide for brain metastasis Endocrine therapy - Not specified Radiotherapy - No concurrent external-beam radiotherapy to the brain - No concurrent whole-brain radiotherapy Surgery - Not specified Other - No other prior or concurrent conventional or investigational systemic agents for brain metastasis



Primary Contact:

Study Chair
Michael A. Vogelbaum, MD, PhD
The Cleveland Clinic

Backup Contact:


Location Contact:

Cleveland, Ohio 44195
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: April 07, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.